ATAI Life Sciences N.V.

NASDAQ: ATAI
$1.52
-$0.07 (-4.4%)
Closing Price on November 21, 2024

ATAI Stock Chart and Intraday Price

ATAI Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 180 VARICK STREET, NEW YORK, NY, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 353.60M USD
Shares Outstanding 166,010,000
ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company’s other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

ATAI Articles

Here is a look of a few of the biggest clinical trial and FDA updates in regards to psychedelics to watch for in 2022.
Here's a quick look at six publicly traded companies developing ways to use psychedelics to treat mental health issues.